Table of Contents ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37852 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Delaware 98-0505495 (State or oth ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37852 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37852 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 98-0505495 (State or other j ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37852 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 98-0505495 (State o ...

1 COMPANY OVERVIEW Dinesh V. Patel, PhD | President & CEO August 4, 2022 This presentation and the accompanying oral presentation contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, product candidates, capital resources, potential m ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37852 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 98-0505495 (State or oth ...

1 Jefferies Global Healthcare Conference Dinesh V. Patel, PhD | President & CEO June 8, 2022 This presentation and the accompanying oral presentation contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, product candidates, capital re ...

| --- | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | A Phase 2 randomized, double-blind, placebocontrolled, multi-center study to evaluate the | | | | | safety and efficacy of the oral, gut-restricted ɑ4β 7 integrin peptide antagonist PN-943 in ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-37852 PROTAGONIST THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of ...

```markdown Part I [Business](index=8&type=section&id=Item%201.%20Business) Protagonist Therapeutics is a biopharmaceutical company developing peptide-based drugs for hematology/blood disorders and inflammatory/immunomodulatory diseases, with lead assets rusfertide and IBD candidates derived from its proprietary peptide technology platform - The company's clinical programs focus on two main areas: hematology/blood disorders and inflammatory/immunomodulatory diseases[25](index=25&type=chunk) - The company's most advanced clinical asset is rusfertide (PTG-300), an injectable hepcidin mimetic for blood disorders like polycythemia vera (PV) and hereditary hemochromatosis (HH)[27](index=27&type=chunk) - The company is developing orally delivered antagonists for inflammatory bowel disease (IBD), including PN-943 (α4β7 antagonist) and PN-235 (IL-23R antagonist), the latter in collaboration with Janssen[33](index=33&type=chunk) [Rusfertide: An Injectable Hepcidin Mimetic](index=12&type=section&id=Rusfertide%3A%20An%20Injectable%20Hepcidin%20Mimetic) Rusfertide is an injectable hepcidin mimetic regulating iron metabolism for disorders like Polycythemia Vera (PV) and Hereditary Hemochromatosis (HH), with a Phase 3 PV trial set for Q1 2022 and positive Phase 2 HH results - Rusfertide is being developed for disorders characterized by excessive red blood cells (RBCs) and iron overload, such as Polycythemia Vera (PV) and Hereditary Hemochromatosis (HH)[42](index=42&type=chunk) - For PV, rusfertide has received Orphan Drug, Fast Track, and Breakthrough Therapy designations from the FDA, as well as Orphan Drug designation from the EMA[37](index=37&type=chunk)[53](index=53&type=chunk) - Following positive Phase 2 results in PV (REVIVE and PACIFIC studies), the company plans to initiate a global Phase 3 trial, VERIFY, in Q1 2022, with enrollment expected to complete in the first half of 2023[32](index=32&type=chunk)[57](index=57&type=chunk) - A Phase 2 proof-of-concept study in HH was completed in Q4 2021, demonstrating a significant reduction in phlebotomies, lower serum iron levels, and reduced liver iron content[61](index=61&type=chunk) - On September 16, 2021, the FDA placed a clinical hold on rusfertide studies due to findings in a mouse carcinogenicity study, which was lifted on October 8, 2021, after the company submitted a Complete Response[29](index=29&type=chunk)[31](index=31&type=chunk) [Inflammatory Bowel Disease (IBD) Programs](index=18&type=section&id=Inflammatory%20Bowel%20Disease%20(IBD)%20Programs) The company is developing two orally delivered peptides for Inflammatory Bowel Disease (IBD), PN-943 (α4β7 integrin antagonist) with Q2 2022 Phase 2 UC data expected, and Janssen-partnered PN-235 (IL-23R antagonist) advancing to Phase 2b for psoriasis and IBD - PN-943 is an oral, gut-restricted α4β7 integrin antagonist for IBD, with enrollment for the Phase 2 IDEAL study in UC completed in Q1 2022 and topline data expected in Q2 2022[34](index=34&type=chunk)[86](index=86&type=chunk) - The company has a worldwide collaboration with Janssen for IL-23R antagonists, and Janssen has decided to advance the second-generation candidate, PN-235, discontinuing PTG-200 and PN-232[36](index=36&type=chunk)[89](index=89&type=chunk) - Janssen initiated a Phase 2b study (FRONTIER 1) of PN-235 in psoriasis in early 2022 and plans a Phase 2 study in IBD in the second half of 2022[38](index=38&type=chunk)[89](index=89&type=chunk) - The company received a **$7.5 million** milestone payment from Janssen in Q4 2021 and is eligible for up to approximately **$900.0 million** in future development-related milestone payments[39](index=39&type=chunk)[40](index=40&type=chunk) [Our Peptide Technology Platform](index=30&type=section&id=Our%20Peptide%20Technology%20Platform) The company utilizes a proprietary technology platform combining molecular design, phage display, and medicinal chemistry to discover and develop constrained peptides as novel drug candidates, including clinical-stage assets and new targets like an oral hepcidin mimetic - The platform engineers structurally constrained peptides designed to combine the advantages of small molecules and injectable antibodies[41](index=41&type=chunk)[99](index=99&type=chunk) - It employs tools like molecular design software (Vectrix™), phage display libraries, and medicinal chemistry to optimize candidates for potency, selectivity, and stability for various delivery forms[100](index=100&type=chunk) - The platform is being used to develop an orally active hepcidin mimetic, which would be complementary to the injectable rusfertide[101](index=101&type=chunk) [Competition](index=32&type=section&id=Competition) Protagonist faces significant competition in polycythemia vera (PV) from drugs like Jakafi® and Besremi®, and in IBD from approved injectable agents and emerging oral therapies including JAK inhibitors, S1P1 modulators, and other α4β7 inhibitors - In PV, competitors include Incyte's Jakafi® (ruxolitinib) and PharmaEssentia's recently approved Besremi® (ropeginterferon alfa-2b)[104](index=104&type=chunk) - In IBD, competition includes injectable anti-integrin (Takeda's Entyvio®) and anti-IL-23 (Abbvie's Skyrizi®, Janssen's Tremfya®) agents[105](index=105&type=chunk)[108](index=108&type=chunk) - Emerging oral IBD competitors include JAK inhibitors (Pfizer's Xeljanz®, Abbvie's Rinvoq®), S1P1 receptor modulators (BMS's Zeposia®), and another oral α4β7 inhibitor from Morphic Therapeutics (MORF-057)[105](index=105&type=chunk)[106](index=106&type=chunk) [Material Agreements](index=34&type=section&id=Material%20Agreements) The company has key agreements including an amended collaboration with Janssen Biotech for IL-23R antagonists, yielding **$87.5 million**, and a research collaboration with Zealand Pharma A/S for a hepcidin mimetic, now fully Protagonist's responsibility - The company has an amended and restated collaboration agreement with Janssen for IL-23R antagonists, receiving a total of **$87.5 million** in payments through Q4 2021[110](index=110&type=chunk) - A 2012 research collaboration with Zealand Pharma A/S was initiated to discover a hepcidin mimetic, with Protagonist later assuming full responsibility for the development program[111](index=111&type=chunk) [Intellectual Property](index=34&type=section&id=Intellectual%20Property) The company protects its technology through 15 issued U.S. patents and over 60 ex-U.S. patents related to clinical assets, expiring between October 2033 and July 2041, alongside trade secrets and confidentiality agreements for its proprietary platform - The company owns or co-owns **15** issued U.S. patents and over **60** granted ex-U.S. patents related to its clinical assets[113](index=113&type=chunk) - Patents and patent applications, if issued, are expected to expire between October 2033 and July 2041, excluding any potential patent term extensions[115](index=115&type=chunk) - The company relies on trade secrets and confidentiality agreements to protect its proprietary technology platform and know-how[112](index=112&type=chunk)[121](index=121&type=chunk) [Manufacturing](index=38&type=section&id=Manufacturing) Protagonist relies entirely on a global network of third-party contract manufacturing organizations (CMOs) for all product candidate production for pre-clinical, clinical, and future commercial supplies, with no plans for in-house facilities - The company does not own or operate manufacturing facilities and has no plans to build any[123](index=123&type=chunk) - It relies on a global network of contract manufacturing organizations (CMOs) in the U.S., Europe, and Asia for all pre-clinical, clinical, and future commercial supplies[123](index=123&type=chunk) [Government Regulation](index=38&type=section&id=Government%20Regulation) The company's operations are subject to extensive regulation by the FDA and comparable foreign authorities across the entire product lifecycle, from pre-clinical studies and clinical trials to manufacturing, marketing approval, labeling, and post-approval monitoring, including reimbursement requirements - The company is subject to substantial regulation by the FDA and other authorities covering research, development, manufacturing, and marketing of its drug candidates[124](index=124&type=chunk) - The FDA drug approval process involves pre-clinical studies, an IND application, three phases of human clinical trials under GCP, and submission of an NDA[126](index=126&type=chunk)[131](index=131&type=chunk)[132](index=132&type=chunk) - The company may utilize expedited programs such as Fast Track Designation and Breakthrough Therapy Designation to accelerate development and review[145](index=145&type=chunk)[146](index=146&type=chunk) - Commercial success depends on securing coverage and adequate reimbursement from third-party payors, and the company is subject to cost-containment measures and healthcare reforms like the ACA[158](index=158&type=chunk)[161](index=161&type=chunk) [Human Capital](index=54&type=section&id=Human%20Capital) As of December 31, 2021, Protagonist had 118 employees, with a strong commitment to diversity, inclusion, and talent retention through competitive benefits, equity programs, and fostering internal growth - As of December 31, 2021, the company had **118** full-time equivalent employees, with **92** in R&D and **26** in G&A[178](index=178&type=chunk) - The company reports a diverse workforce, with nearly **65%** from underrepresented ethnic communities and **51%** identifying as female[178](index=178&type=chunk) - Employee retention and development are key focuses, with competitive benefits including **100%** healthcare premium coverage, 401(k) matching, and an employee stock purchase plan, with approximately **20%** of employees promoted each year[179](index=179&type=chunk)[180](index=180&type=chunk) [Risk Factors](index=57&type=section&id=Item%201A.%20Risk%20Factors) The company faces numerous risks including the COVID-19 pandemic's impact, heavy dependence on clinical-stage candidates, inherent development uncertainty, significant losses, funding needs, reliance on third parties, intense competition, regulatory hurdles, and stock price volatility - The COVID-19 pandemic could continue to adversely impact business, including delays in clinical trial enrollment and operations[188](index=188&type=chunk) - The company is heavily dependent on the success of its clinical-stage product candidates, and failure of any can occur at any stage of the lengthy and expensive clinical development process[195](index=195&type=chunk)[199](index=199&type=chunk) - The company has a history of significant losses (**$409.4 million** accumulated deficit as of Dec 31, 2021) and expects to require substantial additional funding to continue operations[213](index=213&type=chunk)[215](index=215&type=chunk) - Reliance on third parties is a key risk, including the collaboration with Janssen for PN-235 development and the use of contract manufacturers for all drug supply[220](index=220&type=chunk)[228](index=228&type=chunk) - The company's stock price has been and will likely continue to be volatile, and failure to maintain effective internal controls could adversely affect investor confidence[316](index=316&type=chunk)[318](index=318&type=chunk) [Unresolved Staff Comments](index=102&type=section&id=Item%201B.%20Unresolved%20Staff%20Comments) The company reports that it has no unresolved staff comments from the SEC - None[329](index=329&type=chunk) [Properties](index=102&type=section&id=Item%202.%20Properties) The company leases approximately 57,900 square feet of office and laboratory space in Newark, California, under a lease agreement expiring in May 2024, which management deems adequate for the next 12 months - The company leases approximately **57,900** square feet of office and laboratory space in Newark, California, under a lease that expires in May 2024[330](index=330&type=chunk) [Legal Proceedings](index=102&type=section&id=Item%203.%20Legal%20Proceedings) The company is not currently a party to any material legal proceedings, noting that an arbitration proceeding was resolved during the third quarter of 2021 - The company is not currently a party to any material legal proceedings[331](index=331&type=chunk) - An arbitration proceeding with Zealand Pharma A/S was resolved in the third quarter of 2021[331](index=331&type=chunk)[586](index=586&type=chunk) [Mine Safety Disclosures](index=102&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[332](index=332&type=chunk) Part II [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=103&type=section&id=Item%205.%20Market%20for%20Registrant%27s%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) The company's common stock trades on The Nasdaq Stock Market under "PTGX", with two stockholders of record as of February 15, 2022, and no anticipated cash dividends in the foreseeable future as earnings will be retained for business operations - Common stock trades on Nasdaq under the symbol "PTGX"[335](index=335&type=chunk) - As of February 15, 2022, there were two stockholders of record[336](index=336&type=chunk) - The company has never paid cash dividends and does not plan to in the foreseeable future[337](index=337&type=chunk) [Reserved](index=105&type=section&id=Item%206.%20Reserved) This item is reserved [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=105&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) For the year ended December 31, 2021, Protagonist reported a net loss of **$125.6 million**, an increase from **$66.2 million** in 2020, driven by a **69% increase in R&D expenses** to **$126.0 million**, with **$326.9 million** in cash believed sufficient for the next 12 months Financial Highlights (2021 vs. 2020) | Metric | 2021 (in thousands) | 2020 (in thousands) | Change (%) | | :--- | :--- | :--- | :--- | | License and collaboration revenue | $27,357 | $28,628 | (4)% | | Research and development expense | $126,006 | $74,506 | 69% | | General and administrative expense | $27,196 | $18,638 | 46% | | Net loss | $(125,551) | $(66,150) | 90% | - The company had an accumulated deficit of **$409.4 million** as of December 31, 2021[355](index=355&type=chunk) - As of December 31, 2021, cash, cash equivalents, and marketable securities totaled **$326.9 million**[427](index=427&type=chunk) [Results of Operations](index=120&type=section&id=Results%20of%20Operations) Comparing 2021 to 2020, license revenue decreased slightly while R&D expenses surged **69%** to **$126.0 million**, widening the net loss to **$125.6 million**, whereas 2020 saw increased revenue and a reduced net loss compared to 2019 R&D Expenses by Program (2021 vs. 2020, in thousands) | Program | 2021 | 2020 | Change | | :--- | :--- | :--- | :--- | | Rusfertide (PTG-300) | $55,382 | $32,395 | $22,987 | | PN-943 | $37,655 | $23,354 | $14,301 | | PN-235 | $4,777 | $317 | $4,460 | | Preclinical & Discovery | $24,943 | $18,453 | $6,490 | | Milestone to Zealand | $4,000 | $0 | $4,000 | - License and collaboration revenue decreased by **$1.3 million** (**4%**) in 2021 compared to 2020, mainly due to a decrease in services provided under the Janssen agreement, partially offset by an **$8.0 million** cumulative catch-up adjustment from the agreement's amendment[395](index=395&type=chunk) - G&A expenses increased by **$8.6 million** (**46%**) in 2021, primarily due to a **$5.2 million** increase in personnel-related expenses (including **$3.6 million** in stock-based compensation) and a **$1.6 million** increase in consulting expenses[401](index=401&type=chunk) [Liquidity and Capital Resources](index=128&type=section&id=Liquidity%20and%20Capital%20Resources) As of December 31, 2021, the company held **$326.9 million** in cash, cash equivalents, and marketable securities, primarily funded by stock offerings and collaboration payments, with management believing current capital is sufficient for the next 12 months but anticipating future funding needs - The company completed an underwritten public offering in June 2021, raising net proceeds of **$123.8 million**[421](index=421&type=chunk) - Total payments received from Janssen under the collaboration agreement amounted to **$87.5 million** from inception through December 31, 2021[423](index=423&type=chunk) Cash Flow Summary (in thousands) | Cash Flow Activity | 2021 | 2020 | 2019 | | :--- | :--- | :--- | :--- | | Cash used in operating activities | $(107,865) | $(72,484) | $(41,527) | | Cash used in investing activities | $(15,860) | $(90,965) | $(53,710) | | Cash provided by financing activities | $129,923 | $247,626 | $46,036 | - Management believes existing cash will be sufficient to fund operations for at least the next 12 months from the filing date[427](index=427&type=chunk) [Quantitative and Qualitative Disclosures about Market Risk](index=136&type=section&id=Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company's primary market risks relate to interest rate sensitivities on its **$326.9 million** investment portfolio, where a **1%** increase would yield approximately **$2.2 million** in interest income, and minor foreign currency risk - The company is exposed to interest rate risk on its **$326.9 million** portfolio of cash, cash equivalents, and marketable securities[448](index=448&type=chunk) - A hypothetical **1%** increase in interest rates would increase interest income by approximately **$2.2 million**, while a **1%** decrease would reduce it by **$0.5 million**[448](index=448&type=chunk) - Foreign currency exposure is minimal, with **$1.1 million** held in Australia; a **10%** exchange rate fluctuation is not considered material[449](index=449&type=chunk) [Financial Statements and Supplementary Data](index=138&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) This section presents the audited consolidated financial statements for 2021 and 2020, including balance sheets, statements of operations, comprehensive loss, stockholders' equity, and cash flows, with an unqualified opinion from Ernst & Young LLP on both financial statements and internal control over financial reporting Consolidated Balance Sheet Data (As of Dec 31, in thousands) | | 2021 | 2020 | | :--- | :--- | :--- | | Total Assets | $347,695 | $324,468 | | Total Liabilities | $47,674 | $44,862 | | Total Stockholders' Equity | $300,021 | $279,606 | Consolidated Statement of Operations Data (Year Ended Dec 31, in thousands) | | 2021 | 2020 | 2019 | | :--- | :--- | :--- | :--- | | License and collaboration revenue | $27,357 | $28,628 | $231 | | Total operating expenses | $153,202 | $93,144 | $80,752 | | Net loss | $(125,551) | $(66,150) | $(77,187) | | Net loss per share | $(2.71) | $(1.92) | $(2.98) | [Changes in and Disagreements with Accountants on Accounting and Financial Disclosure](index=203&type=section&id=Item%209.%20Changes%20in%20and%20Disagreements%20with%20Accountants%20on%20Accounting%20and%20Financial%20Disclosure) The company reports that there have been no changes in or disagreements with its accountants on accounting and financial disclosure - None[662](index=662&type=chunk) [Controls and Procedures](index=203&type=section&id=Item%209A.%20Controls%20and%20Procedures) Management concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2021, a conclusion affirmed by the unqualified opinion from Ernst & Young LLP - Management concluded that disclosure controls and procedures were effective as of December 31, 2021[663](index=663&type=chunk) - Management concluded that internal control over financial reporting was effective as of December 31, 2021, based on the COSO framework[664](index=664&type=chunk) - The independent auditor, Ernst & Young LLP, issued an unqualified opinion on the effectiveness of the company's internal control over financial reporting[665](index=665&type=chunk)[669](index=669&type=chunk) [Other Information](index=206&type=section&id=Item%209B.%20Other%20Information) The company reports no other information for this item - None[677](index=677&type=chunk) Part III [Directors, Executive Officers, and Corporate Governance](index=207&type=section&id=Item%2010.%20Directors%2C%20Executive%20Officers%2C%20and%20Corporate%20Governance) Information required for this item is incorporated by reference from the company's definitive Proxy Statement for its 2022 Annual Meeting of Stockholders - Information is incorporated by reference from the definitive Proxy Statement for the 2022 Annual Meeting of Stockholders[681](index=681&type=chunk) [Executive Compensation](index=207&type=section&id=Item%2011.%20Executive%20Compensation) Information required for this item is incorporated by reference from the company's definitive Proxy Statement for its 2022 Annual Meeting of Stockholders - Information is incorporated by reference from the definitive Proxy Statement for the 2022 Annual Meeting of Stockholders[684](index=684&type=chunk) [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](index=207&type=section&id=Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholder%20Matters) Information required for this item is incorporated by reference from the company's definitive Proxy Statement for its 2022 Annual Meeting of Stockholders - Information is incorporated by reference from the definitive Proxy Statement for the 2022 Annual Meeting of Stockholders[685](index=685&type=chunk) [Certain Relationships and Related Transactions, and Director Independence](index=207&type=section&id=Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions%2C%20and%20Director%20Independence) Information required for this item is incorporated by reference from the company's definitive Proxy Statement for its 2022 Annual Meeting of Stockholders - Information is incorporated by reference from the definitive Proxy Statement for the 2022 Annual Meeting of Stockholders[686](index=686&type=chunk) [Principal Accounting Fees and Services](index=207&type=section&id=Item%2014.%20Principal%20Accounting%20Fees%20and%20Services) Information required for this item is incorporated by reference from the company's definitive Proxy Statement for its 2022 Annual Meeting of Stockholders - Information is incorporated by reference from the definitive Proxy Statement for the 2022 Annual Meeting of Stockholders[687](index=687&type=chunk) Part IV [Exhibits, Financial Statement Schedules](index=208&type=section&id=Item%2015.%20Exhibits%2C%20Financial%20Statement%20Schedules) This section lists documents filed as part of the Annual Report on Form 10-K, including financial statements referenced from Part II, Item 8, and an index of all exhibits filed or incorporated by reference - This section contains the list of financial statements, notes that financial statement schedules are omitted, and provides an index of all filed exhibits[689](index=689&type=chunk)[690](index=690&type=chunk)[691](index=691&type=chunk) [Form 10-K Summary](index=216&type=section&id=Item%2016.%20Form%2010-K%20Summary) The company provides no summary for this item - None[702](index=702&type=chunk) ```